Skip to main content
. 2017 May 12;96(19):e6769. doi: 10.1097/MD.0000000000006769

Figure 1.

Figure 1

Kaplan–Meier analysis of progression-free survival in a phase II study of FOLFIRINOX as second-line chemotherapy for unresectable pancreatic cancer after gemcitabine-based chemotherapy failure. The median progression-free survival was 2.8 months (95% confidence interval, 2.3–3.1). No patient data were censored.